Pharmatech Names Dr. Maureen Merrifield to Lead Clinical & Regulatory Affairs

HAYWARD, Calif.--(BUSINESS WIRE)--Pharmatech Associates today announced the addition of Maureen Merrifield, Ph.D., as vice president, clinical and regulatory affairs. She is responsible for oversight and management of all clinical and regulatory strategy and support activities relating to regulatory submissions on a global basis.

“We are extremely pleased to welcome Dr. Merrifield to our team of professional consultants,” said Warren Baker, chief executive officer, Pharmatech Associates. “Her outstanding leadership skills and strong experience in regulatory surveillance are important assets that aid in resolving the clinical development issues confronting our clients.”

In over a dozen years in the biotechnology and pharmaceutical industry, Dr. Merrifield has developed regulatory pathways to market for unique and complex investigational products. Her work supports early and late-stage drug development in therapeutic areas such as cell/gene therapy, peptides, monoclonal antibodies, vaccines, small molecule, blood/tissue therapy, and combination products.

Dr. Merrifield holds a Ph.D., and a bachelor of science in chemistry, with honors, from Western University in Ontario, Canada.

About Pharmatech Associates

Pharmatech Associates is a global consultancy for the life science industry, meeting the complex needs of clients with highly experienced scientists and engineering subject matter experts. Pharmatech’s team specializes in Product and Process Development, Facilities and Capital Projects, Regulatory Compliance, and Regulatory Affairs. Pharmatech advises clients that range in size from startups to large multi-national corporations on projects in Asia, Europe and North America from its headquarters in the San Francisco Bay Area. https://pharmatechassociates.com/